BR112022021992A2 - Método de tratamento de câncer em um sujeito em necessidade do mesmo - Google Patents
Método de tratamento de câncer em um sujeito em necessidade do mesmoInfo
- Publication number
- BR112022021992A2 BR112022021992A2 BR112022021992A BR112022021992A BR112022021992A2 BR 112022021992 A2 BR112022021992 A2 BR 112022021992A2 BR 112022021992 A BR112022021992 A BR 112022021992A BR 112022021992 A BR112022021992 A BR 112022021992A BR 112022021992 A2 BR112022021992 A2 BR 112022021992A2
- Authority
- BR
- Brazil
- Prior art keywords
- sirpa
- treatment
- cancer
- subject
- need
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 101150036449 SIRPA gene Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 201000005787 hematologic cancer Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
MÉTODO DE TRATAMENTO DE CÂNCER EM UM SUJEITO EM NECESSIDADE DO MESMO. Trata-se de anticorpos monoclonais anti-SIRPa (mAbs anti-SIRPa), incluindo anticorpos SIRPa multiespecíficos, que são dotados de perfis funcionais distintos, assim como composições relacionadas e métodos de uso de mAbs anti-SIRPa como produtos terapêuticos para a prevenção e tratamento de cânceres sólidos e hematológicos. Também são fornecidas sequências de aminoácidos de anticorpos monoclonais anti-SIRPa exemplificativos.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063018177P | 2020-04-30 | 2020-04-30 | |
US202063071732P | 2020-08-28 | 2020-08-28 | |
US202063107200P | 2020-10-29 | 2020-10-29 | |
PCT/US2021/030163 WO2021222746A2 (en) | 2020-04-30 | 2021-04-30 | THERAPEUTIC SIRPα ANTIBODIES |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022021992A2 true BR112022021992A2 (pt) | 2023-01-03 |
Family
ID=78373977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022021992A BR112022021992A2 (pt) | 2020-04-30 | 2021-04-30 | Método de tratamento de câncer em um sujeito em necessidade do mesmo |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230279108A1 (pt) |
JP (1) | JP2023524238A (pt) |
CN (1) | CN116234572A (pt) |
AU (1) | AU2021264006A1 (pt) |
BR (1) | BR112022021992A2 (pt) |
WO (1) | WO2021222746A2 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11434291B2 (en) | 2019-05-14 | 2022-09-06 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
WO2024105180A1 (en) | 2022-11-16 | 2024-05-23 | Boehringer Ingelheim International Gmbh | Predictive efficacy biomarkers for anti-sirpa antibodies |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2484638C (en) * | 2003-09-11 | 2008-03-25 | Ecopia Biosciences Inc. | Polyene polyketides and methods of production |
ES2579323T3 (es) * | 2007-07-16 | 2016-08-09 | Genentech, Inc. | Anticuerpos anti-CD79B e inmunoconjugados y métodos de uso |
SG11201406762QA (en) * | 2012-01-20 | 2014-11-27 | Genzyme Corp | Anti-cxcr3 antibodies |
AU2018216032B2 (en) * | 2017-02-06 | 2022-04-07 | Orionis Biosciences BV | Targeted chimeric proteins and uses thereof |
WO2019173291A1 (en) * | 2018-03-09 | 2019-09-12 | Phanes Therapeutics, Inc. | Anti-cd73 antibodies and uses thereof |
-
2021
- 2021-04-30 AU AU2021264006A patent/AU2021264006A1/en not_active Withdrawn
- 2021-04-30 BR BR112022021992A patent/BR112022021992A2/pt not_active Application Discontinuation
- 2021-04-30 JP JP2022566033A patent/JP2023524238A/ja not_active Withdrawn
- 2021-04-30 US US17/997,524 patent/US20230279108A1/en not_active Abandoned
- 2021-04-30 WO PCT/US2021/030163 patent/WO2021222746A2/en active Application Filing
- 2021-04-30 CN CN202180047164.8A patent/CN116234572A/zh not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP2023524238A (ja) | 2023-06-09 |
CN116234572A (zh) | 2023-06-06 |
WO2021222746A2 (en) | 2021-11-04 |
AU2021264006A1 (en) | 2022-12-01 |
WO2021222746A3 (en) | 2022-01-20 |
US20230279108A1 (en) | 2023-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202092410A1 (ru) | Конъюгаты камптотецина с пептидом | |
EP4242324A3 (en) | Aptamer barcoding | |
AU2017228470A8 (en) | Combination therapy with anti-CD73 antibodies | |
BR112022021992A2 (pt) | Método de tratamento de câncer em um sujeito em necessidade do mesmo | |
PH12018501220A1 (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
PE20170585A1 (es) | Moleculas de union a antigeno biespecificas activadoras de celulas t | |
BR112016016916A8 (pt) | uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae) | |
BR112018068702A2 (pt) | inibidores bicíclicos em ponte de menin-mll e métodos de uso | |
BR112018068703A2 (pt) | inibidores substituídos de menin-mll e métodos de uso | |
BR112018005573A2 (pt) | ?polipeptídeos de ligação a cd3? | |
WO2016077734A3 (en) | Nk cells with an increased antibody-dependent cellular toxicity (adcc) against tumors | |
ZA201804654B (en) | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates | |
BR112017007170A2 (pt) | anticorpos anti-ox40 humanizados e suas utilizações | |
JOP20190002A1 (ar) | أجسام مضادة (أنتي – بي دي – 1) وطريقة الإنتاج وطريقة استخدام كل منهم | |
BRPI0812878C1 (pt) | anticorpo isolado ou parte funcional do mesmo, vetor, método para produzir um anticorpo ou uma parte funcional do mesmo, para produzir uma célula produtora de anticorpo e para produzir um anticorpo capaz de se ligar especificamente a rsv, composição, e, uso de um anticorpo ou parte funcional do mesmo ou de uma composição ou de vetor | |
BR0309254A (pt) | Uso de um anticorpo anti-ctla-4 | |
ECSP11011338A (es) | Anticuerpos biespecíficos anti-her | |
MX2022003930A (es) | Conjugados de péptido de camptotecina. | |
EA201190210A1 (ru) | Ингибиторы связывания киназы с белком | |
MX2021013850A (es) | Anticuerpo contra tigit y uso del mismo. | |
BR112022000876A2 (pt) | Anticorpos imunomoduladores e métodos de uso destes | |
MX2021010116A (es) | Anticuerpo anti-pd-l1 y uso de este. | |
BR112022005114A2 (pt) | Anticorpo, composição farmacêutica, métodos para tratar câncer e para produzir um conjugado anticorpo-fármaco e um anticorpo, ácido nucleico, vetor, célula hospedeira, e, conjugado anticorpo-fármaco | |
BR112022008552A2 (pt) | Moléculas de ligação multiespecíficas de scfv de terminal-n | |
BR112017025872A2 (pt) | proteínas de ligação multiespecíficas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25G | Requested change of headquarter approved |
Owner name: ARCH ONCOLOGY, INC. (US) |
|
B10A | Cessation: cessation confirmed |